GO:0034276 kynurenic acid biosynthetic process: Neuroprotective Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034276 describes the biochemical reactions that produce kynurenic acid (4-hydroxyquinoline-2-carboxylic acid), an endogenous tryptophan metabolite with neuroprotective and immunomodulatory properties.
• Kynurenic acid is synthesized primarily through the kynurenine pathway, where kynurenine aminotransferases (KATs) catalyze the irreversible transamination of kynurenine to kynurenic acid.
• Kynurenic acid acts as an antagonist at ionotropic glutamate receptors and the alpha7 nicotinic acetylcholine receptor, and as an agonist at GPR35, modulating neurotransmission and inflammation.
• Dysregulation of kynurenic acid biosynthesis is implicated in schizophrenia, neurodegenerative diseases, and metabolic disorders, making it a target for therapeutic intervention.
• The ketogenic diet and certain natural compounds can enhance kynurenic acid production, contributing to neuroprotection in the eye and brain.
• CRISPR-based models (knockout, knock-in, overexpression) of KAT enzymes and kynurenine pathway genes enable causal dissection of kynurenic acid biology in health and disease.
Description
Kynurenic acid (KYNA) is a metabolite of the kynurenine pathway, which is the major route of tryptophan catabolism. The biosynthetic process that generates KYNA is annotated in the Gene Ontology as GO:0034276, kynurenic acid biosynthetic process. This term encompasses the enzymatic steps that convert kynurenine to kynurenic acid, primarily through the action of kynurenine aminotransferases (KATs). KYNA is unique among kynurenine pathway metabolites because it is not further metabolized and is excreted, acting as a terminal product with significant biological activity. Researchers study this process because KYNA modulates glutamatergic and nicotinic neurotransmission, influences immune responses, and has been linked to neuropsychiatric and neurodegenerative disorders. Understanding its biosynthesis is essential for developing therapeutic strategies that target the kynurenine pathway.
kynurenic acid biosynthetic process At A Glance
| GO ID | GO:0034276 |
|---|---|
| GO term | kynurenic acid biosynthetic process |
| Ontology | biological_process |
| Synonym | kynurenine pathway; kynurenic acid biosynthesis; kynurenic acid formation; kynurenic acid synthesis; 4-hydroxyquinoline-2-carboxylic acid biosynthetic process |
| Major function | Production of kynurenic acid, an endogenous antagonist of ionotropic glutamate receptors and alpha7 nicotinic receptors, and agonist of GPR35 |
| Key enzymes | Kynurenine aminotransferases (KAT1, KAT2, KAT3, KAT4) |
| Substrate | Kynurenine, derived from tryptophan via indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) |
| Cofactor | Pyridoxal phosphate (PLP) for aminotransferase activity |
| Pathway branch | Kynurenine pathway branch leading to kynurenic acid |
What Is GO:0034276?
GO:0034276, kynurenic acid biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of kynurenic acid, 4-hydroxyquinoline-2-carboxylic acid. This process is a branch of the kynurenine pathway and involves the transamination of kynurenine to kynurenic acid, typically catalyzed by kynurenine aminotransferases. The term is a biological process and includes synonyms such as kynurenic acid anabolism, biosynthesis, formation, and synthesis, as well as kynurenine pathway.
Why Is kynurenic acid biosynthetic process Important in Cell Biology?
The kynurenic acid biosynthetic process is critically important because kynurenic acid is a neuroactive metabolite that modulates synaptic transmission and provides neuroprotection. It acts as an antagonist at NMDA and alpha7 nicotinic receptors, and as an agonist at GPR35, influencing processes ranging from cognition to inflammation. Dysregulation of KYNA production has been associated with schizophrenia, where elevated KYNA levels may contribute to cognitive deficits, and with neurodegenerative conditions where KYNA may be protective. Moreover, KYNA regulates adipose tissue energy homeostasis and inflammation, linking this pathway to metabolic disorders. Therefore, understanding and manipulating this biosynthetic process has broad therapeutic potential.
• Kynurenic acid is a broad-spectrum antagonist of ionotropic glutamate receptors, protecting neurons from excitotoxicity.
• It acts as an antagonist at alpha7 nicotinic acetylcholine receptors, modulating cholinergic transmission.
• KYNA is an agonist at GPR35, regulating energy homeostasis and inflammation in adipose tissue.
• Altered KYNA levels are implicated in schizophrenia and cognitive dysfunction.
• The ketogenic diet may exert neuroprotective effects in the eye partly by increasing KYNA production.
• Natural molecules such as kynurenic acid, pantethine, and alpha-lipoic acid show neuroprotective potential.
• Kynurenic acid in the gut-brain axis influences normal appetite regulation.
• Quinic acid alleviates neuroinflammation via gut microbial tryptophan metabolites, including kynurenic acid.
• Kynurenine pathway inhibitors are being explored as therapeutic agents, with KYNA as a key node.
• CRISPR models of KAT enzymes enable causal studies of KYNA biosynthesis in disease.
What Happens During kynurenic acid biosynthetic process?
Tryptophan Catabolism to Kynurenine
In simple terms: Tryptophan is first converted to kynurenine, the direct precursor of kynurenic acid.
The kynurenine pathway begins with the oxidation of L-tryptophan to N-formylkynurenine by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO), followed by rapid deformylation to kynurenine. This step is rate-limiting and determines the flux into downstream branches, including kynurenic acid synthesis. In the brain, kynurenine can also be transported from the periphery across the blood-brain barrier.
Transamination of Kynurenine to Kynurenic Acid
In simple terms: Kynurenine is converted to kynurenic acid by aminotransferase enzymes using pyridoxal phosphate.
Kynurenine aminotransferases (KATs) catalyze the irreversible transamination of kynurenine to kynurenic acid, using pyridoxal phosphate (PLP) as a cofactor. Four KAT isoenzymes (KAT1, KAT2, KAT3, KAT4) have been identified, with KAT1 and KAT2 being the most studied in the brain. This reaction competes with other kynurenine pathway branches, such as the production of 3-hydroxykynurenine and quinolinic acid, which are neurotoxic.
Regulation of Kynurenic Acid Synthesis
In simple terms: The amount of kynurenic acid produced is controlled by enzyme activity and substrate availability.
Kynurenic acid biosynthesis is regulated by the availability of kynurenine, the activity of KAT enzymes, and the presence of cofactors such as PLP. Factors that influence KAT activity include pH, substrate concentration, and post-translational modifications. Additionally, the balance between KYNA production and other kynurenine pathway branches is critical; for example, inflammatory cytokines can shift the pathway toward neurotoxic metabolites. The ketogenic diet has been shown to increase KYNA levels in the eye, suggesting dietary modulation of this pathway.
Transport and Action of Kynurenic Acid
In simple terms: Once made, kynurenic acid is released and acts on receptors to modulate neuronal and immune functions.
Kynurenic acid is not further metabolized and is transported out of cells. It acts as an antagonist at ionotropic glutamate receptors (including NMDA receptors) and at alpha7 nicotinic acetylcholine receptors, and as an agonist at GPR35. Through these receptors, KYNA modulates synaptic plasticity, neurotransmitter release, and inflammatory signaling. In adipose tissue, KYNA-GPR35 signaling regulates energy homeostasis and inflammation. In the gut-brain axis, KYNA influences appetite regulation.
Role of Kynurenic Acid in Neuroprotection
In simple terms: Kynurenic acid protects neurons by blocking excessive glutamate signaling and reducing inflammation.
By antagonizing glutamate receptors, KYNA reduces excitotoxicity, a key mechanism of neuronal damage in neurodegenerative diseases. It also modulates neuroinflammation through GPR35 and other pathways. The neuroprotective activity of the ketogenic diet in the eye has been linked to increased KYNA production. Natural molecules such as kynurenic acid, pantethine, and alpha-lipoic acid have shown neuroprotective effects in preclinical studies.
Key Genes Involved in GO:0034276 kynurenic acid biosynthetic process
The following genes and proteins are central to the kynurenic acid biosynthetic process, including enzymes, transporters, and receptors that mediate its effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KAT1 (KYAT1) | Kynurenine aminotransferase 1; catalyzes kynurenine to kynurenic acid | Target for modulating KYNA levels in neuropsychiatric disorders |
| KAT2 (KYAT2) | Kynurenine aminotransferase 2; major brain isoform for KYNA synthesis | Genetic variants linked to schizophrenia risk |
| KAT3 (KYAT3) | Kynurenine aminotransferase 3; mitochondrial isoform | Less studied; potential role in metabolic tissues |
| KAT4 (KYAT4) | Kynurenine aminotransferase 4; broad substrate specificity | May contribute to KYNA synthesis in peripheral tissues |
| IDO1 | Indoleamine 2,3-dioxygenase 1; rate-limiting enzyme for tryptophan catabolism to kynurenine | Inflammation-induced; target for cancer immunotherapy |
| IDO2 | Indoleamine 2,3-dioxygenase 2; alternative tryptophan catabolic enzyme | Less active; potential immunomodulatory role |
| TDO2 | Tryptophan 2,3-dioxygenase; liver enzyme for tryptophan catabolism | Regulates systemic kynurenine levels |
| KMO | Kynurenine 3-monooxygenase; diverts kynurenine to neurotoxic branch | Inhibition may shunt kynurenine toward KYNA |
| KYNU | Kynureninase; converts kynurenine to anthranilic acid | Competes with KYNA synthesis |
| GPR35 | G protein-coupled receptor; mediates KYNA effects on energy homeostasis and inflammation | Target for metabolic and inflammatory diseases |
| GRIN1 | NMDA receptor subunit 1; KYNA antagonizes NMDA receptors | Key mediator of KYNA neuroprotection |
| GRIN2A | NMDA receptor subunit 2A; KYNA antagonism modulates synaptic plasticity | Implicated in schizophrenia and neurodegeneration |
| CHRNA7 | Alpha7 nicotinic acetylcholine receptor; KYNA acts as antagonist | Linked to cognitive deficits in schizophrenia |
| SLC7A5 | L-type amino acid transporter; transports kynurenine across blood-brain barrier | Regulates brain KYNA synthesis |
| SLC7A8 | L-type amino acid transporter; transports kynurenine | Potential target for modulating brain KYNA |
| AADAT | Kynurenine aminotransferase II (mitochondrial); also known as KAT2 | Key enzyme for brain KYNA production |
| CCBL1 | Kynurenine aminotransferase I (cytoplasmic); also known as KAT1 | Major enzyme for KYNA synthesis in liver and brain |
| CCBL2 | Kynurenine aminotransferase III; mitochondrial | Contributes to KYNA synthesis in specific tissues |
How Is kynurenic acid biosynthetic process Regulated?
The kynurenic acid biosynthetic process is regulated at multiple levels. The availability of the substrate kynurenine is controlled by the activity of IDO1, IDO2, and TDO2, which are influenced by inflammatory cytokines such as interferon-gamma. KAT enzyme activity is modulated by pyridoxal phosphate availability, pH, and post-translational modifications. Additionally, the balance between KYNA production and the neurotoxic branch (via KMO and KYNU) determines the net neuroprotective vs. neurotoxic outcome. Hormonal and dietary factors, such as the ketogenic diet, can also enhance KYNA synthesis. In adipose tissue, KYNA-GPR35 signaling is part of a feedback loop regulating energy homeostasis and inflammation.
kynurenic acid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KAT2 (KYAT2) | Schizophrenia; cognitive deficits | KAT2 knockout mice; point mutation models |
| GPR35 | Metabolic syndrome; inflammation | GPR35 knockout mice; overexpression models |
| IDO1 | Cancer; immune evasion | IDO1 knockout tumor models; knock-in reporter |
| KMO | Neurodegeneration; Huntington's disease | KMO knockout mice; point mutation |
| CHRNA7 | Schizophrenia; nicotine addiction | CHRNA7 knockout mice; knock-in humanized models |
Schizophrenia and Cognitive Disorders
Elevated kynurenic acid levels in the brain have been associated with cognitive deficits in schizophrenia. KYNA antagonizes alpha7 nicotinic acetylcholine receptors and NMDA receptors, both of which are implicated in schizophrenia pathophysiology. Genetic variants in KAT enzymes may influence KYNA production and disease risk. Targeting the kynurenic acid biosynthetic process could offer novel therapeutic approaches for cognitive symptoms.
Neurodegenerative Diseases
In neurodegenerative conditions such as Alzheimer's and Parkinson's diseases, KYNA may exert neuroprotective effects by reducing excitotoxicity and inflammation. The ketogenic diet, which increases KYNA levels, has shown neuroprotective activity in the eye, suggesting potential for retinal neurodegeneration. However, excessive KYNA may also contribute to cognitive impairment, highlighting the need for precise modulation.
Metabolic and Inflammatory Disorders
Kynurenic acid regulates adipose tissue energy homeostasis and inflammation through GPR35. Dysregulation of KYNA production has been linked to obesity and metabolic syndrome. Gut microbial metabolites, including KYNA, influence neuroinflammation and appetite via the gut-brain axis. Quinic acid alleviates high-fat diet-induced neuroinflammation by modulating gut microbial tryptophan metabolites, including KYNA.
Cancer and Immune Regulation
The kynurenine pathway is a key immune checkpoint, with IDO1 overexpression in tumors leading to local tryptophan depletion and immunosuppression. KYNA, as a downstream metabolite, may also modulate immune responses through GPR35. Inhibitors of the kynurenine pathway are being explored in cancer immunotherapy, and understanding KYNA biosynthesis is relevant to these efforts.
From kynurenic acid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does KAT2 loss alter brain KYNA levels and cognition? | KAT2 knockout mouse |
| Does a specific KAT2 point mutation affect enzyme activity? | KAT2 point-mutation knock-in mouse |
| Can GPR35 activation by KYNA be tracked in vivo? | GPR35-tagged knock-in mouse |
| Does overexpression of KAT1 increase KYNA and protect against excitotoxicity? | KAT1 overexpression transgenic mouse |
| How does IDO1 knockout affect systemic kynurenine and KYNA levels? | IDO1 knockout mouse |
| Can CRISPR library screening identify regulators of KYNA biosynthesis? | Genome-wide CRISPR knockout library in cell lines |
How to Study the kynurenic acid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Kynurenic acid and pathway metabolite levels | Quantification in plasma, brain, cells |
| KAT activity assay | Enzymatic conversion of kynurenine to KYNA | Assessing KAT function and inhibition |
| CRISPR knockout screening | Genes required for KYNA production | Identifying novel pathway regulators |
| RNA-seq | Transcriptional changes in kynurenine pathway genes | Evaluating gene expression under conditions |
| Western blot | Protein levels of KATs, IDO1, GPR35 | Validating knockout or overexpression |
| Electrophysiology | Receptor antagonism by KYNA | Measuring NMDA or alpha7 nAChR currents |
| Behavioral tests | Cognitive and affective phenotypes | Assessing KYNA modulation in vivo |
| Metabolic phenotyping | Energy homeostasis and inflammation | Studying GPR35-KYNA axis |
Metabolomics and Mass Spectrometry
Quantification of kynurenic acid and other kynurenine pathway metabolites is typically performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This method allows sensitive detection of KYNA in plasma, brain tissue, and cell culture supernatants. Stable isotope-labeled internal standards improve accuracy. Metabolomics can reveal flux through the pathway under different genetic or pharmacological conditions.
Enzymatic Activity Assays
Kynurenine aminotransferase activity is measured by incubating cell or tissue lysates with kynurenine and pyridoxal phosphate, followed by quantification of kynurenic acid production using HPLC or LC-MS/MS. These assays are used to assess the impact of genetic mutations or inhibitors on enzyme function.
Genetic and CRISPR Screening
CRISPR knockout, knock-in, and overexpression models enable causal interrogation of genes in the kynurenic acid biosynthetic process. Genome-wide CRISPR screens can identify novel regulators of KYNA production. Reporter cell lines expressing fluorescent or luminescent sensors under the control of KYNA-responsive promoters can be used for high-throughput screening.
Behavioral and Physiological Testing
Animal models with altered KYNA biosynthesis are assessed using behavioral tests for cognition, anxiety, and sensorimotor gating. Electrophysiology can measure KYNA effects on synaptic transmission. Metabolic phenotyping, such as glucose tolerance tests and body composition analysis, is used to study KYNA-GPR35 signaling in energy homeostasis.
How CRISPR Can Be Used to Study GO:0034276 kynurenic acid biosynthetic process
Knockout
CRISPR knockout of KAT genes (e.g., KAT1, KAT2) in cell lines or mice abolishes or reduces kynurenic acid production, enabling studies of its physiological roles. Knockout of GPR35 can reveal KYNA-dependent signaling in energy homeostasis and inflammation. IDO1 knockout models are used to study the impact of reduced kynurenine availability on KYNA synthesis.
Point Mutation
Introducing specific point mutations in KAT enzymes via CRISPR can mimic human genetic variants associated with altered enzyme activity or disease risk. For example, mutations in KAT2 identified in schizophrenia patients can be modeled to assess their effect on KYNA production and cognitive phenotypes. Point mutations in GPR35 can dissect ligand binding and signaling.
Knock-in
Knock-in of reporter tags (e.g., FLAG, GFP) into endogenous KAT or GPR35 loci allows visualization and quantification of protein expression and localization. Knock-in of humanized KAT genes into mouse models can facilitate translational studies. Conditional knock-in using Cre-lox systems enables tissue-specific expression.
Overexpression
Overexpression of KAT enzymes or GPR35 via CRISPR activation (CRISPRa) or transgenic constructs can increase KYNA production or signaling, providing gain-of-function models. These are useful for testing neuroprotective or anti-inflammatory effects of enhanced KYNA. Overexpression of IDO1 can increase kynurenine flux, potentially boosting KYNA if KAT capacity is sufficient.
How EDITGENE Supports kynurenic acid biosynthetic process Research
Researchers studying kynurenic acid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in KYNA production or signaling. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling precise functional dissection of the kynurenine pathway.
Contact EDITGENE today to design your custom CRISPR model for kynurenic acid biosynthetic process research.
Frequently Asked Questions About kynurenic acid biosynthetic process
What is kynurenic acid biosynthetic process?
It is the biochemical pathway that produces kynurenic acid, an endogenous metabolite of tryptophan, primarily through the transamination of kynurenine by kynurenine aminotransferases.
What is GO:0034276?
GO:0034276 is the Gene Ontology identifier for kynurenic acid biosynthetic process, a biological process term describing the reactions that form kynurenic acid.
What genes are involved in kynurenic acid biosynthetic process?
Key genes include KAT1, KAT2, KAT3, KAT4 (kynurenine aminotransferases), IDO1, IDO2, TDO2 (tryptophan catabolism), and GPR35 (receptor mediating KYNA effects).
How is kynurenic acid synthesized?
Kynurenic acid is synthesized from kynurenine by kynurenine aminotransferases (KATs) in a pyridoxal phosphate-dependent transamination reaction.
What is the role of kynurenic acid in the brain?
Kynurenic acid acts as an antagonist at NMDA and alpha7 nicotinic receptors, providing neuroprotection by reducing excitotoxicity and modulating neurotransmission.
Is kynurenic acid involved in schizophrenia?
Yes, elevated kynurenic acid levels have been associated with cognitive deficits in schizophrenia, possibly through alpha7 nicotinic receptor antagonism.
Can diet affect kynurenic acid production?
The ketogenic diet has been shown to increase kynurenic acid levels in the eye, contributing to neuroprotection. Gut microbial metabolites also influence KYNA production.
What is the kynurenine pathway?
The kynurenine pathway is the major route of tryptophan catabolism, producing several metabolites including kynurenic acid, quinolinic acid, and NAD+.
How can CRISPR be used to study kynurenic acid biosynthesis?
CRISPR knockout, knock-in, and overexpression models of KAT enzymes, IDO1, and GPR35 allow causal studies of KYNA production and its physiological effects.
What diseases are linked to kynurenic acid dysregulation?
Schizophrenia, neurodegenerative diseases, metabolic disorders, and cancer have been linked to altered kynurenic acid levels or signaling.
Conclusion
The kynurenic acid biosynthetic process (GO:0034276) is a critical branch of the kynurenine pathway that produces a neuroactive and immunomodulatory metabolite. Its dysregulation is implicated in schizophrenia, neurodegeneration, and metabolic disorders, making it a promising therapeutic target. Advances in CRISPR-based models and metabolomics are enabling precise dissection of this pathway, and EDITGENE offers comprehensive services to support such research.
References
- 1. Agudelo LZ et al.. 2018. Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation.. Cell Metab 27(2):378-392.e5 PMID: 29414686
- 2. Li S et al.. 2024. Quinic acid alleviates high-fat diet-induced neuroinflammation by inhibiting DR3/IKK/NF-κB signaling via gut microbial tryptophan metabolites.. Gut Microbes 16(1):2374608 PMID: 38972055
- 3. Zarnowski T et al.. 2017. Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye.. Curr Med Chem 24(32):3547-3558 PMID: 28486923
- 4. Stone TW. 2001. Kynurenic acid antagonists and kynurenine pathway inhibitors.. Expert Opin Investig Drugs 10(4):633-45 PMID: 11281814
- 5. Tóth F et al.. 2021. Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid.. Int J Mol Sci 22(1) PMID: 33401674
- 6. Stone TW. 2020. Does kynurenic acid act on nicotinic receptors? An assessment of the evidence.. J Neurochem 152(6):627-649 PMID: 31693759
- 7. Javitt DC. 2014. Distress intolerance, kynurenic acid, and schizophrenia.. JAMA Psychiatry 71(7):749-50 PMID: 24806109
- 8. Pan L et al.. 2025. The gut-brain axis mechanism of normal appetite induced by kynurenic acid.. Cell Rep 44(5):115659 PMID: 40317720
